Lights and Shadows of Bacillus Calmette-Guérin (BCG)-exposed and BCG-unresponsive Definitions: A Practical Overview

Area of Science:

• Urology
• Oncology
• Cancer Research

Background:

• Non-muscle-invasive bladder cancer (NMIBC) recurrence after bacillus Calmette-Guérin (BCG) treatment necessitates careful management strategies.
• Current definitions of NMIBC recurrence impact treatment decisions and patient outcomes.

Discussion:

• Patients experiencing late relapses or those exposed to BCG may benefit from additional intravesical instillations.
• BCG-unresponsive NMIBC warrants consideration for clinical trials or radical cystectomy.
• The optimal management of BCG-intolerant NMIBC remains an area requiring further investigation and evidence-based guidelines.

Key Insights:

• Refined definitions of NMIBC recurrence after BCG therapy are crucial for personalized treatment selection.
• Distinguishing between BCG-responsive, unresponsive, and intolerant disease is key to effective NMIBC management.
• Further research is needed to establish best practices for BCG-intolerant bladder cancer patients.

Outlook:

• Future research should focus on developing novel treatment strategies for BCG-unresponsive and BCG-intolerant NMIBC.
• Improved diagnostic criteria and risk stratification may enhance treatment efficacy and reduce recurrence rates.
• Personalized treatment algorithms based on recurrence patterns and BCG response will be essential for optimizing NMIBC care.